156 related articles for article (PubMed ID: 36889765)
1.
Zhang KJ; Qu Z; Pszenica E; Hafron JM; Zhang PL; Brown RE
Ann Clin Lab Sci; 2023 Jan; 53(1):3-13. PubMed ID: 36889765
[TBL] [Abstract][Full Text] [Related]
2. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
[TBL] [Abstract][Full Text] [Related]
3. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
Henske EP; Cornejo KM; Wu CL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
[TBL] [Abstract][Full Text] [Related]
4. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
5. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
6. Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up.
Shah RB; Mehra R
Adv Anat Pathol; 2024 Mar; 31(2):105-117. PubMed ID: 37899532
[TBL] [Abstract][Full Text] [Related]
7. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
[TBL] [Abstract][Full Text] [Related]
8. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
[TBL] [Abstract][Full Text] [Related]
9. Renal Cell Carcinoma With Fibromyomatous Stroma-The Whole Story.
Shah RB
Adv Anat Pathol; 2022 May; 29(3):168-177. PubMed ID: 35249990
[TBL] [Abstract][Full Text] [Related]
10. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
11. [Eosinophilic, solid, and cystic renal cell carcinoma (ESC-RCC)].
Hartmann A; Agaimy A
Pathologe; 2021 Nov; 42(6):565-570. PubMed ID: 34550432
[TBL] [Abstract][Full Text] [Related]
12. Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.
Palsgrove DN; Li Y; Pratilas CA; Lin MT; Pallavajjalla A; Gocke C; De Marzo AM; Matoso A; Netto GJ; Epstein JI; Argani P
Am J Surg Pathol; 2018 Sep; 42(9):1166-1181. PubMed ID: 29975249
[TBL] [Abstract][Full Text] [Related]
13. Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex.
Lerma LA; Schade GR; Tretiakova MS
Hum Pathol; 2021 Oct; 116():1-11. PubMed ID: 34153307
[TBL] [Abstract][Full Text] [Related]
14. Low-grade oncocytic tumor of kidney harboring TSC/MTOR mutation: clinicopathologic, immunohistochemical and molecular characteristics support a distinct entity.
Zhang HZ; Xia QY; Wang SY; Shi MJ; Wang SY
Virchows Arch; 2022 May; 480(5):999-1008. PubMed ID: 35099634
[TBL] [Abstract][Full Text] [Related]
15. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
[TBL] [Abstract][Full Text] [Related]
16. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
[TBL] [Abstract][Full Text] [Related]
17. Are Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinomas Characterized by Somatic Tuberous Sclerosis Gene Mutations?
Parilla M; Kadri S; Patil SA; Ritterhouse L; Segal J; Henriksen KJ; Antic T
Am J Surg Pathol; 2018 Jul; 42(7):911-917. PubMed ID: 29668487
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting.
Kapur P; Brugarolas J; Trpkov K
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627070
[TBL] [Abstract][Full Text] [Related]
19. Concordance of MTOR Pathway Mutations and the Diagnosis of Renal Low-Grade Oncocytic Tumor (LOT).
Siegmund SE; Al-Obaidy KI; Tsai HK; Idrees MT; Akgul M; Acosta AM; Hirsch MS
Int J Surg Pathol; 2024 Apr; 32(2):316-330. PubMed ID: 37357748
[TBL] [Abstract][Full Text] [Related]
20. Pathology of hereditary renal cell carcinoma syndromes: Tuberous sclerosis complex (TSC).
Machacek ME; Wu CL; Cornejo KM
Semin Diagn Pathol; 2024 Jan; 41(1):8-19. PubMed ID: 37993384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
